IRWD Q1 2023 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$104M+6.7% YoY

Gross Profit

$104M99.7% margin

Operating Income

$60M57.8% margin

Net Income

$46M43.9% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

-2.9%

Cash Flow

Operating Cash Flow

$80M

Free Cash Flow

$80M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$448M

Stockholders' Equity

$707M

Cash & Equivalents

$742M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$98M	+6.7%
Gross Profit	$104M	$87M	+19.7%
Operating Income	$60M	$58M	+3.9%
Net Income	$46M	$39M	+17.8%

Revenue Segments

Collaborative arrangements revenue

$104M99%

Collaborative arrangement, other agreements

$580,0001%

Collaborative arrangement, collaboration and license agreements

$91,0000%

Geographic Segments

North America

$700,00050%

Canada and Mexico

$700,00050%